Follow the Pundits
Tag: dividend stocks
🚢 TORM (TRMD): 8% Dividend. Dirt-Cheap Valuation. So Why Did the CEO Sell Everything?
TORM looks almost too good to be true: an 8% dividend, dirt-cheap valuation, strong earnings, and analysts calling it a Buy. Then the CEO sold every share he owned. Here's what investors should really focus on.
Marriott (MAR): Great Company, Bad Price? 🏨📉
Marriott (MAR) is one of the best businesses in hospitality—but with insider selling and stretched valuation, is the stock running out of room? 🏨
UNP Stock Analysis 2026: Is Union Pacific a “Core Compounder” or Just Fully Priced?
Union Pacific (NYSE: UNP) is the institutional-grade backbone of American freight. With elite operating efficiency, steady dividend growth, and near-ATH pricing, the question isn’t whether it’s good — it’s whether you’re paying too much for quality.
Hedge Funds Like Royalty Pharma: Should Retail Wear the Crown?
Royalty Pharma isn’t a biotech moonshot — it’s a cash-collecting royalty king. Hedge funds are buying, buybacks are flowing, and dividends keep compounding. 👑💊
Kenvue Director Jeff Smith of Starboard Value Buys Shares of KVUE; He Must Love Kimberly-Clark. Should You?
A $111 million insider buy. Nearly 100% institutional ownership. A blockbuster merger with Kimberly-Clark. Kenvue suddenly looks boring… in a very interesting way.
Bill Ackman Still Holds Nearly 10% of Restaurant Brands International — Should You Join the Feast?
Bill Ackman hasn’t lost his appetite for Restaurant Brands International. He still owns nearly 10% of QSR — home of Burger King, Tim Hortons, Popeyes, and Firehouse Subs. Should investors join the activist investor at the table?
Estée Laudee Must Be Looking Pretty: Insider Buys, Big Believers, and a Beautiful Turnaround?
Michael Burry just doubled his stake in Estée Lauder, and he’s not alone. With a new CEO, insider confidence, and strong institutional backing, is this iconic beauty stock about to glow up? 💄📈